Answer
Yes, patients receiving Replagal (agalsidase alfa) may develop antibodies against the protein, with low-titre IgG antibodies observed in approximately 24% of treated male patients.
Sources for this answer
- Replagal 1mg/ml concentrate for solution for infusionTakeda UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 20Document updated
Sources checked